Insiders Trades
Zai Lab Ltd Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 06 Jul 2026.
Zai Lab Ltd: what insiders have been doing
Zai Lab Ltd is a Healthcare & Pharma company based in Shanghai, People's Republic of China. Its directors and officers file their transactions with SEC (Form 4). From 18 October 2025 to 18 October 2026, the disclosure feed for Zai Lab Ltd logged 77 filings by 12 insiders.
Both sides are active: 2 purchases worth €58k and 22 sales worth €3.3M, from 1 insider and 5 insiders respectively. No amount is published for 4 filings, which the totals therefore leave out. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. On the buying side, the filings list 1 senior executive among the declarants. Du Ying filed the largest sale, €861k, on 15 May 2026, which represents 0.041% of the company's market value.
The last insider purchase was made public on 6 July 2026, 104 days ago. Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
Across the 5,810 companies tracked on its exchange, the median is 19 filings; at 77 filings, this issuer sits above that mark. The full history, which starts in 2021, counts 8 purchases against 51 sales. For the fiscal year to 31 December 2025, the annual 10-K puts revenue at 460.2 m USD and net income at -175.5 m USD.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Cytosorbents Corp. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
248
Thresholds
n/a
Buy Volume
€908,908
8 ops. · all time
Sell Volume
€10M
51 ops. · all time
Who traded when
BuySaleFrazor Titus Edmondson III8 sales
Yajing Chen7 sales
Ying Du7 sales
Amado Rafael5 sales
Richard Gaynor2 buys1 sale
Smiley Joshua L1 buy2 sales
+2 other insiders
Since the insiders bought
- +16.3%Entry US$19.35 · Close 14 Oct 2026 US$22.50
- -29.5%Entry US$31.92 · Close 14 Oct 2026 US$22.50
- -47.8%Entry US$67.78 · Close at T+365 US$35.40
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 20,934 of 24,148 companies
25.4
score / 100
Value20
Quality31
FCF yld-6.3%
Earn yld-6.7%
EV/EBITDA·
ROE-27%
Gross mgn58%
Net mgn-38%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$22.50
Analyst consensus
12 analysts1.33/5
US$24.25Target US$33.14(+47%)US$50.00
Income statement
RevenueUS$460.2M
Gross profitUS$269.1M58% margin
EBITDA-US$158.2M-34% margin
Net income-US$175.5M-41.9% margin
Valuation
PER (forward)-10.7x
P/Book4.2x
Beta0.72
Balance sheet & cash
Market capUS$2.5B
Total debtUS$224.3M
Free Cash Flow-US$164.2M
Debt / Equity42%
Profitability & ownership
ROE-26.9%
ROA-14.7%
% insiders2.1%
% institutions38.5%
Last declaration on 5 October 2026
Declarations248 total
920 sharesAmerican Depositary SharesSEC:0000905148-26-004359:0
315 shares@ US$25.500.0003% mcap1.2% of flowAmerican Depositary SharesSEC:0000905148-26-004359:1
98,653 shares@ US$26.17770.085% mcap70.5% of flowAmerican Depositary SharesSEC144:0001959173-26-006280
260 shares@ US$27.000.0002% mcap1.0% of flowAmerican Depositary SharesSEC144:0001959173-26-006213
1,250 sharesAmerican Depositary SharesSEC:0000905148-26-003804:0
427 shares@ US$25.900.0004% mcap1.6% of flowAmerican Depositary SharesSEC:0000905148-26-003804:1
8,506 shares@ US$25.000.0071% mcap10.9% of flowAmerican Depositary SharesSEC144:0001959173-26-005923
619 shares@ US$25.000.0005% mcap2.2% of flowAmerican Depositary SharesSEC144:0001959173-26-005899
1,736 shares@ US$19.050.0011% mcap4.5% of flowAmerican Depositary SharesSEC:0000905148-26-003169:0
Canonical exit: 29 Sept 2026 (T+90)
6,250 sharesAmerican Depositary SharesSEC:0000905148-26-003121:0
2,264 sharesAmerican Depositary SharesSEC:0000905148-26-003121:1
14,600 sharesAmerican Depositary SharesSEC:0000905148-26-003123:0
4,103 sharesAmerican Depositary SharesSEC:0000905148-26-003123:1
2,264 shares@ US$17.46130.0017% mcap5.8% of flowAmerican Depositary SharesSEC144:0001959173-26-004920
4,103 shares@ US$17.46130.0031% mcap2.2% of flowAmerican Depositary SharesSEC144:0001959173-26-004917
25 of 248 declarations
About Zai Lab Ltd
Zai Lab Ltd (NASDAQ: ZLAB) is a U.S.-listed biopharmaceutical company trading on the NASDAQ market in the United States, with a dual operating footprint across the United States and China. For international investors, it fits the profile of a growth-oriented biotech platform that combines a commercial base in China with global research and development capabilities. The company was founded in 2014 by Dr. Samantha Du with the goal of building a leading global biopharma company able to discover, develop, and commercialize innovative therapies addressing major unmet medical needs. Its headquarters are in Cambridge, Massachusetts and Shanghai, underscoring a binational model that gives the company access to talent, capital, clinical infrastructure, and regulatory expertise in both markets. ([zailaboratory.com](https://www.zailaboratory.com/about-us/))
Zai Lab’s business model is built around in-licensed assets, strategic partnerships, and internally developed programs. The company operates across oncology, immunology, neuroscience, and infectious disease, and describes itself as a fully integrated biopharmaceutical company with capabilities spanning discovery, clinical development, regulatory affairs, manufacturing, and commercialization. In China, Zai Lab has built a meaningful commercial platform and states that it has eight products on the market, which provides a revenue base to support ongoing R&D investment. ([zailaboratory.com](https://www.zailaboratory.com/about-us/))
Read moreShow less
From a competitive standpoint, Zai Lab differentiates itself by combining local commercial execution in China with the ability to advance select assets globally. Its marketed portfolio includes ZEJULA, VYVGART, NUZYRA, and XACDURO, while the pipeline includes near-term launch and regulatory opportunities such as KarXT and TIVDAK. The company is also placing increasing strategic emphasis on zocilurtatug pelitecan, or “zoci,” a DLL3-targeted antibody-drug conjugate that management describes as a potential best-in-class and first-in-class asset in small cell lung cancer. In 2026, Zai Lab said KarXT launch preparations were underway, TIVDAK remained under regulatory review, and positive Phase 3 data for povetacicept and elegrobart created additional growth opportunities for the regional business. ([ir.zailaboratory.com](https://ir.zailaboratory.com/news-releases/news-release-details/zai-lab-announces-first-quarter-2026-financial-results-and))
Geographically, the company operates with teams in the United States, Greater China, and Europe, and lists locations including Cambridge, San Francisco, San Diego, Beijing, Shanghai, Suzhou, Hong Kong, and Taiwan. That footprint supports a strategy that relies on cross-border R&D, regional regulatory execution, and commercialization in one of the world’s most important pharmaceutical markets. ([zailaboratory.com](https://www.zailaboratory.com/about-us/))
Recent developments have been material. In 2026, Zai Lab reported the China NMPA approval of COBENFY for adult schizophrenia, the NMPA approval of AUGTYRO for NTRK-positive solid tumors, the launch of a global Phase 3 study for zoci in second-line extensive-stage small cell lung cancer, and encouraging clinical data presented at AACR 2026. First-quarter 2026 revenue was $99.6 million, while cash, short-term investments, and current restricted cash totaled $761.3 million at March 31, 2026. For investors, Zai Lab offers exposure to China’s biopharma growth runway and a globally relevant pipeline, but with the clinical and regulatory risk typical of a NASDAQ-listed biotech company. ([ir.zailaboratory.com](https://ir.zailaboratory.com/news-releases/news-release-details/zai-lab-announces-first-quarter-2026-financial-results-and))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
